<SEC-DOCUMENT>0000950170-25-046978.txt : 20250331
<SEC-HEADER>0000950170-25-046978.hdr.sgml : 20250331
<ACCEPTANCE-DATETIME>20250328174439
ACCESSION NUMBER:		0000950170-25-046978
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20250328
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20250331
DATE AS OF CHANGE:		20250328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		25788088

	BUSINESS ADDRESS:	
		STREET 1:		350 BAY STREET
		STREET 2:		SUITE 100 #6009
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94133
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		350 BAY STREET
		STREET 2:		SUITE 100 #6009
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94133
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>fgen-20250328.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-28T16:14:58.7155+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:fgen="http://www.fibrogen.com/20250328" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_c36c21ad-1f48-4640-bde6-1360d6564698" name="dei:AmendmentFlag" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857">false</ix:nonNumeric><ix:nonNumeric id="F_631fbbce-5715-496b-a4df-b6dd3d7c9676" name="dei:EntityCentralIndexKey" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857">0000921299</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="fgen-20250328.xsd"/></ix:references><ix:resources><xbrli:context id="C_4bb04693-9dd4-426b-9b06-35eeae323857"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000921299</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-28</xbrli:startDate><xbrli:endDate>2025-03-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9c7f8ae-98ef-4c60-810b-cbbec462118c" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_c193617b-1307-4c26-9582-abb65c0f7d0a" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 28, 2025</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_77dd1ddc-58a8-4d9c-a559-27b556a7b181" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FIBROGEN, INC.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:41%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_82f16d6c-ae3b-45de-bef8-d382e8f0660e" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3adfda85-2c14-4b87-a765-e485bf9a5506" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-36740</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_95031a97-f325-431b-8152-27e81bd31a5b" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">77-0357827</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_166a18a3-1256-4939-9a30-f51814b0e38e" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">350 Bay Street</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2f3ba177-c711-4796-9188-534aba47a5eb" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 100 #6009 </span></ix:nonNumeric></span><span></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_98ef52b4-0947-455e-ae37-2d32ec4b59d8" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">San Francisco</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_f890849f-e6b0-46cf-8401-3d3ba007503c" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ebc0affd-0dd3-40ce-b07a-32030a4251d4" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94133</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_523ecf8d-7680-4173-958a-357c657e7378" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">415</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_b0606b94-6e37-4f59-82c5-6c4c82820f77" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">978-1200 </span></ix:nonNumeric></span><span></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0f0519cc-f528-4d9c-a94b-22115d30504c" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_642e908b-cf41-44d7-8a8f-087a72848fba" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_94ba20c3-b7bb-48ba-874e-f6d1f0af8952" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c69ba67-c61a-49b3-9e12-acb1922c5d07" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9f7ca7ba-c759-4581-a887-f1582c66770c" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, $0.01 par value</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f89a7fe4-3d50-4828-9a5f-abe8bdca6fe6" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FGEN</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_524bfee7-92fd-402f-ac0b-d7582069a169" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_fef85712-aca1-4504-951c-f6513ee378e2" contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7.01.	Regulation FD Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 28, 2025, FibroGen, Inc. issued a press release in which it announced the peer-reviewed publication titled &#8220;A Phase 1, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients with Metastatic Castration Resistant Prostate Cancer&#8221; in the Journal of Clinical Oncology. The manuscript includes the complete results from the Fortis Therapeutics-sponsored Phase 1 study of FOR46 (now known as FG-3246), a potential first-in-class anti-CD46 antibody drug conjugate with a monomethyl auristatin E-containing payload, in patients with metastatic castration-resistant prostate cancer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in Exhibit 99.1 shall be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in Exhibit 99.1 shall be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by FibroGen, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">           (d)    Exhibits</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.198%;box-sizing:content-box;"/>
    <td style="width:1.04%;box-sizing:content-box;"/>
    <td style="width:86.763%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.75pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.75pt solid #ffffff03;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;border-bottom:0.75pt solid #000000;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="fgen-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Press Release dated March 28, 2025.</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.02in;padding-left:0.02in;vertical-align:top;padding-bottom:0.02in;padding-right:0.02in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:44%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FIBROGEN, INC.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 28, 2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ John Alden</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">John Alden<br/>General Counsel</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>fgen-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img3914235_0.jpg" alt="img3914235_0.jpg" style="width:178px;height:45px;"></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancer</font></div></div>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC expected by mid-2025</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SAN FRANCISCO, March 28, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the peer-reviewed publication titled </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;A Phase 1, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients with Metastatic Castration Resistant Prostate Cancer&#x201d;</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the Journal of Clinical Oncology. The manuscript includes the complete results from the Fortis Therapeutics-sponsored Phase 1 study of FOR46 (now known as FG-3246), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with an MMAE-containing payload, in patients with metastatic castration-resistant prostate cancer (mCRPC).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;I am excited to see the results from the Phase 1 monotherapy study of FOR46 (FG-3246) published in the Journal of Clinical Oncology. This is the first clinical trial targeting CD46 in patients with prostate cancer, and the totality of the data highlights the promising potential of FG-3246 anti-cancer activity, especially when considering the unselected, heavily pre-treated patient population in the trial. The trial results provide key insights into the potential clinical impact of targeting CD46 in the treatment of mCRPC and support its further development in this disease space with high unmet need,&#x201d; said Dr. Rahul Aggarwal, Professor of Medicine at the University of California San Francisco, and Principal Investigator of the study.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;We are looking forward to advancing FG-3246 in the clinic and remain on track for initiating the Phase 2 monotherapy study by mid-2025 as well as disclosing topline results from the combination trial of FG-3246 and enzalutamide in the second half of 2025,&#x201d; added Thane Wettig, Chief Executive Officer of FibroGen. &#x201c;FG-3246 represents a potential first-in-class, non-PSMA approach to treating mCRPC and we, along with the medical community, are excited about the potential for CD46 to become a next generation target in the prostate cancer treatment paradigm.&#x201d;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Phase 1 study was a multi-center, first-in-human, open label dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity as measured by the decline of prostate-specific antigen (PSA) from baseline, objective tumor response rate in patients with measurable disease, and radiographic progression free survival (rPFS). The completed Phase 1 trial includes a total of 56 patients from the dose-escalation and dose-expansion cohorts. Notably, patients were biomarker unselected and heavily pre-treated, having received a median of 5 lines of therapy prior to receiving FG-3246.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key highlights from the publication include:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The maximally tolerated dose of FG-3246 was 2.7 mg/kg by adjusted body weight (AjBW) every 3 weeks </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The most frequent adverse events were consistent with other MMAE-based ADCs and included infusion related reactions (48.2%), neutropenia (41.1%), and peripheral neuropathy (32.1%).</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ocular adverse events were infrequent, which may be a distinguishing feature compared with other MMAE-based ADCs</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efficacy observed in the RECIST-evaluable set of 25 patients:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Confirmed objective response rate was 20% with median duration of response of 7.5 months</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:16.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.999615998463994%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x25aa;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All objective responses observed at a starting dose of 2.7 mg/kg or higher</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disease control rate was 80% with duration of treatment exceeding 24 weeks in 12 patients (48%)</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSA50 response rate of 36% in 39 evaluable patients</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of eight evaluable patients who received docetaxel in the castration-sensitive setting, four (50%) achieved a confirmed PSA50 response</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Median radiographic progression-free survival of 8.7 months in all 40 subjects in the efficacy analysis set </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Of 15 evaluable baseline tumors, 12 (80%) were positive for CD46 expression by immunohistochemistry</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FG-3246 responders were found to have a significantly higher frequency of effector T cells and lower frequency of immunosuppressive myeloid cells</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company anticipates initiating the Phase 2 monotherapy dose optimization study of FG-3246 in patients with mCRPC by mid-2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FG-3246 is also being evaluated in combination with enzalutamide in an investigator-sponsored study with topline results from the Phase 2 portion of the study anticipated in 2H 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About the Phase 1 Study</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FOR46-001 (</font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NCT03575819</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) is a Phase 1, dose-escalation study sponsored by Fortis Therapeutics to evaluate multiple doses of IV-administered FG-3246 (also known as FOR46) in patients with mCRPC who have progressive disease on at least one ARSI, followed by a dose-expansion cohort, to evaluate the safety, tolerability, PK, biological activity, and preliminary evidence of anti-tumor activity of FG-3246 in this patient population.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Thirty-three (33) patients were enrolled in the dose-escalation phase of the study at doses between 0.1 mg/kg and 3.0 mg/kg every three weeks (Q3W), with adjusted body weight dosing (AjBW) used at most dose levels above 2.1 mg/kg. Safety and tolerability of FG-3246 were evaluated in the dose-escalation period of the study.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Twenty-three (23) patients were enrolled in the dose-expansion period of the study; 18 patients with adenocarcinoma mCRPC (Cohort 1) and five patients with neuroendocrine prostate cancer (Cohort 2). All patients in the expansion cohorts were treated at 2.7 mg/kg AjBW to a maximum of 270 mg every three weeks.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The safety profile of FG-3246 was characterized, and anti-tumor activity of FG-3246 in adenocarcinoma patients dosed at &#x2265; 1.2 mg/kg was evaluated.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About Metastatic Castration-Resistant Prostate Cancer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prostate cancer is the second most common malignancy in men, contributing significantly to male mortality rates. Approximately 13% of men will be diagnosed with prostate cancer at some point during their lifetime. There are about 65,000 drug treatable mCRPC cases in the U.S. annually and 5-year survival in mCRPC is approximately 30%.</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About FG-3246</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FG-3246 (also known as FOR46) is a potential first-in-class, fully human antibody-drug conjugate (ADC), exclusively in-licensed from Fortis Therapeutics, and is being developed by FibroGen for metastatic castration-resistant prostate cancer and other tumor types. FG-3246 binds to an epitope of CD46, a cell receptor target, that induces internalization upon antibody binding, is present at high levels in prostate cancer and other tumor types and demonstrates very limited expression in most normal tissues. FG-3246 is comprised of an anti-CD46 antibody, YS5, linked to the anti-mitotic agent, MMAE, which is a clinically and commercially validated ADC payload. FG-3246 has demonstrated anti-tumor activity in both preclinical and clinical studies. FG-3246 is currently in an ongoing Phase 1/2 study being conducted at UCSF to evaluate it in combination with enzalutamide with topline data from the Phase 2 portion of the study expected in the second half of 2025, and a biomarker trial using a PET biomarker for CD46 using the same antibody backbone. We anticipate the initiation of the Phase 2 monotherapy dose optimization trial in metastatic castration-resistant prostate cancer by mid-2025. FG-3246 is an investigational drug and not approved for marketing by any regulatory authority.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About FibroGen</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (&#x7231;&#x745e;&#x5353;&#174;, EVRENZO</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">www.fibrogen.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This release contains forward-looking statements regarding FibroGen&#x2019;s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its collaboration partners Fortis and UCSF. These forward-looking statements include, but are not limited to, statements regarding the efficacy, safety, and potential clinical or commercial success of FibroGen products and product candidates, and statements about FibroGen&#x2019;s plans and objectives. These forward-looking statements are typically identified by use of terms such as &#x201c;may,&#x201d; &#x201c;will&#x201d;, &#x201c;should,&#x201d; &#x201c;on track,&#x201d; &#x201c;could,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;estimate,&#x201d; &#x201c;predict,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue&#x201d; and similar words, although some forward-looking statements are expressed differently. FibroGen&#x2019;s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen&#x2019;s Annual Report on Form 10-K for the most recent fiscal year, and any more recent Quarterly Reports on Form 10-Q, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">References:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Seer.cancer.gov </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">https://seer.cancer.gov/statfacts/html/prost.html</font></font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For Investor Inquiries:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">David DeLucia, CFA</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Senior Vice President and Chief Financial Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ir@fibrogen.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img3914235_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img3914235_0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !G 9@# 2(  A$! Q$!_\0
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M<OS$<X'I5JSW.>I.I'6*N>LMTKSN:TU+0-8UK5?"\/\ :5JLB1W&A>?L5I
M9'AW<1R!2/E^ZV><'FN?\*Z_\3VT'2M6$.C^*["[M4N#&=UA>)N7.P\%"P)P
M?E'(QQ2^&_C5H&BS:M_PD%CJWA:62[:69M4M3Y"2%5!03)N3@ <DCK5^S?34
MYWC(77/[OK_GL/\ B3XPB\?1:5X*\.WX2_UJ8IJ*@8FL[./!N-Z_P,>$ /=N
M..:N^#9(?A7XFOO"-W<"W\.RP-J>BSW,H"6\:@">VW$]$^^O^RS=A7$^%;Z'
M58?$WQ<M=4T^VO[R;[+I[,-T<MI$2L<$H7YB\C$L,?/RGTH\>,OQ0\-SZ[KL
MUGX9U#PWY6HV'A_694C^SW'9KMB0&2090*/EP><MP*E&UHDX>2K7K]]O0[SQ
M%XBNO%.AZC>QK+9^#880[7D<C17.H#.&6/@&./MNZMGC Y/H6FZ?:Z38P6=G
M#';6D$8CBBC& J@8 'X5Y$?CIH_Q \%1R^&M!U/Q+!>6H:9[>'R[2V/R[DDF
MDP#M)Q^[#]#6M=6OC_7-)NKS6=<L?!VG"(R^3HD0N+I4"Y(:>4;<XSRJ @@<
MUGRNRN=;E9MLV-!US_A(/BCK\"0/]FT6VAMOM'G$HTTF79=G3<H"\]?FQWKO
M1TKRS]G71Y+'X;V^HW,UQ=7>M3R:E)/=MOE=7.(RS=R8U0_C7J.[/:B>]B,-
M=T^:6[U'T4F[(KD?B[XTN/AU\,/%'BBUMX[NYTC3IKV."8D)(R*2%)'.#BL]
MW8ZO,Z[-%?G+_P //_%^/^1,T7_O]-_C1_P\^\7?]"9HO_?Z;_XJNOZI6[&'
MMH=S]&LT5^<G_#S[Q?\ ]"9HO_?Z;_XJAO\ @J!XO53CP9HO'_3:;_XJG]4K
M=A>WAW/T<I,UY'I_Q^L-/_9XL?BCXEA6QMY+!;N6VM<MF1FVK&F>I9L 9]:^
M?/A9_P %(H/%GQ"M-&\2>&8=#T;4;A;>VOH;HL;8L<*9L\$9P"5QCKCM6,:,
MY)M+8T=2*:39]OTM>9_M"?$^\^#/PEUKQ=8V<.H75AY6RWN"RH^^15.<<]#7
MSS^SE^W1XB^-GQ@T?P?J'AK2].M+Z*XD:YMI9&=?+B9P "<<D8_&IC3E*+DE
MHARG&+LS[1I::M.K,L**** "BBB@ HHHH **** "BBD- "T5B^*O%FC^"- O
M=<US4(=,TFS3S)[J=L*@SC\3G@ <DG%?#_Q4_P""F$D=]+9?#[P_%-;(Q4:E
MJY/[ST*1KT'7J3U'2MJ=&=7X41*<8[L^^J*_)E_V^OC:[;AXDL0,Y"C2H/R^
M[71>$O\ @H[\4=#F_P")W#I/B2$MDB2V%NP&.BF/ ]^172\#52,?K$#]1**\
M3^ /[5O@SX_1&VTN632M>B3?-H]Z0)>F28V'$BCID8/'05[6#FN&47!VDK&Z
MDI:H6BBBD4%%%% !1110 4444 %%%% !1110 E(?NT,<+6#9^+]/N=8GTN1V
MM+Y)'CCANAY;7 4 L\0/+H-P^8<9IDRDH[D/BR\U?2(X-3TV/[9!:DF\T\ !
MY8N[1G'WUZA>C=*>OB*ZU*UAO-#LX-5LYE#QW#70C5P?3Y6_'./2MW<,<=:\
MF\4>.-)^"_B(0B9;G3M2WW$FB68\R[MI3R9D7=A(6/#;MJJQSN&2"TA/5:,D
M^&$VL^'YO$'A.&TMI_[)OFFB22Y*F.VN"98QD1X;YC*/H!FO*_BY\39]4T>+
MPWH-_8W=UXEO98Y='MK5KJ_C16*R<!P &,1 +!1S]X=:U_'G_"1KXST;Q3KZ
M3^%M UF-M'N+/P_(9-0D!.^V$LR+D,[C8!%@KO/SD4G[(O@ V+:YXEN[*&V*
MW,^F:=$OS/#"DSL^]OXG+':7SSL_&NF%HIS?0\G%Q=2<**^U^1B^&_V;/&'C
M#5+76_$":1\/7A ^S6_A@R+<0!1\AX;RPW&26#D=%85H^(_V=?&&AW7]LZ/J
M6G^-M8MYA/:W7BD2/>0X.?+63=M*8_@9<9YZ\U]/TK+Q6?MI&_U"DE[C<7Y,
M^5_AG\4-5\-^(-;\/>*K6S\/SZO!-J-MHT]L]K'%<KA9(XI&9E=7&'&#U#<#
M//;?$'Q9K6J?!_3[5K*W2^\41VNGVVRYR=TX7)QLXPI)-=!^T)\,[;XB?#^[
M9;.VN=9TH&_TYKF,.OFH"=C<?<8 J0.QKP[X:KK/BS7/"TW@P3BQT;3!JDFB
M^('DEMX;AU\M(X9<;@"I=E/S*,<#((K>/++WEH>=B/;T?W<KROI?_@'TOI-U
MJ7A_18K<^'F^S64"Q0P6-TLTK*H 50'"#H.YK)CGD^*&I"-H;BU\,:?)'([>
M8H^WW(Y,1*DYCC(PPSAG&,D YY*Z^,'_  D6I6?@_6K2?P9?79:._GN)P$
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MU4S1N%?FE^Q3X\^+WQ0^,UI#)XYUN_\ #]@GVG5A?W)N(C$#Q& ^<%VP,C!
MR:]I_:>_;RM/AEJUYX6\#P6^L^(8,QW6HS'=;6C]T4 _/(._8'@YY%9RP\U/
MV:U9:JQY>9GV)NI-U?C?XF_:V^+WBJ[$\_CO5K,KG$>ER?9$Y/<1XS^-='X#
M_;F^+G@F: 2Z^/$=E$</;:S&)6<9[R#Y_P <UM]2J6T9"Q$3];J@NKN&RMYK
MBXE6&"%#)))(=JHH&22>P KR3]G3]I+P]^T+X;DNM/4Z=K=J!]NTF1]SPY.
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M'ZKD<94U^G/[*?Q%G^)G[-.CZA=DM?V=I+IURQ!PSQ*55@2><ILR?7-?%O\
MP4:UBRU3]H**WM)4EFL-(@M[G8>4DWR.$/H0KJ?^!5]+_P#!/NWDA_9AO'<D
MK+?WC(#V&Q1_,5ZE>\Z$)RW..G[M221^8]O;R74T<$*&2:601HH&<L3@"OU6
M^ _[%'@/X>>#[,>(]!L?%/B.XB66\N=3@6:.-V )CC1A@*IX!QD\\\X'YA^
MO^1X\/?]A&#_ -&"OW-Z9QZ48RI**C%,*$4VVSPSXW-H/[.'P,\:^(O!>@Z;
MX;U"2W2%9=,LHXB9G;RXG8  -M,F>>G-?F+\%_AC?_''XJ:1X8BNFCEU&=I+
MN\?YF2-<M+)_M-C./4U^AG_!131[W4OV=Y;JVF$=OI^I6T]TF2/,0DQ@8[X=
MU/X5\I_\$[=6LM-_:*B@ND1IKW3;B&V=L?)(,.2,]RJL./6EAWRT)36XZFLU
M%['Z(?#7X'^"?A/HL>F^'= L[8;%6:ZDB#SW!'\4CD98YS[#/%>2?M3?L@>&
M_BCX3U36/#NCV^E^-;=&N(9K,+"MZP&3'*.A)'1N#D#G%?3(XJ&^F2&SN))&
M"1K&S,S=  #DUYL:DXRYKZG5*,6K6/Q=^ OQ-O?@[\6] \10?*D%R+>\@D)
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M2W]Q+)A3*R!B,X''0=J_*+XF6-OI?Q&\5V5K$MO:V^J7444,8PL:"5@J@>P
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>fgen-20250328.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-28T16:14:58.9946+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.fibrogen.com/20250328" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:fgen="http://www.fibrogen.com/20250328" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="fgen-20250328.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 28, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 28,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">FIBROGEN, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0357827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">350 Bay Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100 #6009 <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">978-1200 <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FGEN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ).-?%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ).-?%H6,!OB[P   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL].PS ,AU\%Y=ZZ30>"J.L%Q DD)":!N$6)
MMT5K_B@Q:O?VM&'KA. !.,;^Y?-GR:T*0OF(+]$'C&0P78VV=TFHL&9[HB
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ DXU\6I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M4$L! A0#%     @ DXU\6A8P&^+O    *P(  !$              ( !PP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ DXU\6IE<G",0!@  G"<
M !,              ( !X0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " "3C7Q:I3'R.VT$  !8$0  &               @($B"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ DXU\6I^@&_"Q @  X@P
M  T              ( !Q0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "3
MC7Q:EXJ[',     3 @  "P              @ &A#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " "3C7Q:.JJBYT !   \ @  #P              @ &*$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ DXU\6B0>FZ*M    ^ $  !H
M             ( !]Q$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ DXU\6F60>9(9 0  SP,  !,              ( !W!(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  )A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="fgen-20250328.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="fgen-20250328.htm">fgen-20250328.htm</File>
    <File>fgen-20250328.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "fgen-20250328.htm": {
   "nsprefix": "fgen",
   "nsuri": "http://www.fibrogen.com/20250328",
   "dts": {
    "inline": {
     "local": [
      "fgen-20250328.htm"
     ]
    },
    "schema": {
     "local": [
      "fgen-20250328.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_4bb04693-9dd4-426b-9b06-35eeae323857",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fgen-20250328.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4bb04693-9dd4-426b-9b06-35eeae323857",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "fgen-20250328.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.fibrogen.com/20250328/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-25-046978-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-046978-xbrl.zip
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M&BJW,4GU4A:-]Z+)69<$.VB*@3$45>>D8$LN1 RR)YIH--830<4%**O8R:P
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MUHI7M^ZLPN*2T'.6O#:+1_7BT8LO^NTU\4".SS_M-?OY(/K\_U!+ P04
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MO\G 3ZL,F[-E Y8V;%FDX".56YG*W]V%9H-U2\<7YV,F;G(16E 9DP5+910
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M&P(R7N'B+].",!&Y=0(#29S<?L.V=@^Z@Q?;'9:)PFJ$LI+#A_UN_\6V@W?
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M6#YVAG <8(@\Y@ A0\+HKOLR%8M.54A),;#TS6;T !$R,,*);\ H$;.Z:@W
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M9F40!DNLFF28/"\+?A8.;_H+?BE >0D-*^$>:9K/_*7#!'<RA_5$47W@T*4
MKT@2I?&IIS=AS+,9.1ZI=&F6K<M33'4MDY <ARG'K<>NYP,,VCU2"YEU_8%H
M^"72(N0%*ECAO!Q82I"R$ ^LP\7'6FM.!=9_S"UE @:L [^"&Q(ZI:(^:,\7
MS]96RA&KTI %;K:V_ JFFRG0;HF/L^.8BIP>X!S_6P90EW@3ZU4OP8Y:N<6Q
MX*9KZ0OK$SYOBZ:>!3"Z$*1 P2*OGCCP7"C0[X(N 4?8>]PS=?TD#F2.K<W-
MT<Z.61[;#DHTJB^S$]LTV:& 01=_7?&%6[%]2DS[)3R^RG3!+ZC*Y?.5Z5?\
M&H]0%3\7X')TV/CUR3,EQ*7(\(BE?TM *><89HQ*[.C.D7PML9(3@:(_1_*9
MTDGJ_]P85WR:2O0!$_=MI<57MF!?IM+BY0YF0G[XRTM"'3_\/U!+ 0(4 Q0
M   ( ).-?%K&MWB)#A4  !S    1              "  0    !F9V5N+3(P
M,C4P,S(X+FAT;5!+ 0(4 Q0    ( ).-?%HPB#6SA @  !UA   1
M      "  3T5  !F9V5N+3(P,C4P,S(X+GAS9%!+ 0(4 Q0    ( ).-?%K6
MAM[J7!4  -23   /              "  ? =  !F9V5N+65X.3E?,2YH=&U0
52P4&      ,  P"[    >3,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>fgen-20250328_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fgen-20250328.xsd" xlink:type="simple"/>
    <context id="C_4bb04693-9dd4-426b-9b06-35eeae323857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000921299</identifier>
        </entity>
        <period>
            <startDate>2025-03-28</startDate>
            <endDate>2025-03-28</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_c36c21ad-1f48-4640-bde6-1360d6564698">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_631fbbce-5715-496b-a4df-b6dd3d7c9676">0000921299</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_f9c7f8ae-98ef-4c60-810b-cbbec462118c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_c193617b-1307-4c26-9582-abb65c0f7d0a">2025-03-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_77dd1ddc-58a8-4d9c-a559-27b556a7b181">FIBROGEN, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_82f16d6c-ae3b-45de-bef8-d382e8f0660e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_3adfda85-2c14-4b87-a765-e485bf9a5506">001-36740</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_95031a97-f325-431b-8152-27e81bd31a5b">77-0357827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_166a18a3-1256-4939-9a30-f51814b0e38e">350 Bay Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_2f3ba177-c711-4796-9188-534aba47a5eb">Suite 100 #6009 </dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_98ef52b4-0947-455e-ae37-2d32ec4b59d8">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_f890849f-e6b0-46cf-8401-3d3ba007503c">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_ebc0affd-0dd3-40ce-b07a-32030a4251d4">94133</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_523ecf8d-7680-4173-958a-357c657e7378">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_b0606b94-6e37-4f59-82c5-6c4c82820f77">978-1200 </dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_0f0519cc-f528-4d9c-a94b-22115d30504c">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_642e908b-cf41-44d7-8a8f-087a72848fba">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_94ba20c3-b7bb-48ba-874e-f6d1f0af8952">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_2c69ba67-c61a-49b3-9e12-acb1922c5d07">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_9f7ca7ba-c759-4581-a887-f1582c66770c">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_f89a7fe4-3d50-4828-9a5f-abe8bdca6fe6">FGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_524bfee7-92fd-402f-ac0b-d7582069a169">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_4bb04693-9dd4-426b-9b06-35eeae323857"
      id="F_fef85712-aca1-4504-951c-f6513ee378e2">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
